Depomed (DEPO) Surges On FDA Approval of Shingles Drug, Triggering $48 Million Payment
Tweet Send to a FriendGet Alerts DEPO Hot Sheet
Up)
Trade DEPO Now!
Shares of Depomed, Inc. (Nasdaq: DEPO) are up 44% in pre-open trading Monday following news late Friday that the US FDA has approved GRALISE Tablets for once-daily treatment of post-herpetic neuralgia, or pain following healing of the rash associated with shingles.
GRALISE was developed by Depomed under the code name DM-1796 and is licensed to Abbott Products, Inc. (NYSE: ABT) in the U.S., Canada and Mexico. The approval of GRALISE triggers a milestone payment of $48 million from Abbott to Depomed
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
GRALISE was developed by Depomed under the code name DM-1796 and is licensed to Abbott Products, Inc. (NYSE: ABT) in the U.S., Canada and Mexico. The approval of GRALISE triggers a milestone payment of $48 million from Abbott to Depomed
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
- Tableau Software (DATA) IPO now indicated $45-$48
- Elliott Management said to take significant stake in NetApp (NTAP) - Bloomberg
Create E-mail Alert Related Categories
FDA, Hot FDA News, Momentum Movers
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
